Connect Biopharma Holdings Ltd (CNTB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Connect Biopharma Holdings Ltd stock (CNTB) is currently trading at $3.13. Connect Biopharma Holdings Ltd PS ratio (Price-to-Sales) is 202.49. Analyst consensus price target for CNTB is $7.90. WallStSmart rates CNTB as Sell.
- CNTB PE ratio analysis and historical PE chart
- CNTB PS ratio (Price-to-Sales) history and trend
- CNTB intrinsic value — DCF, Graham Number, EPV models
- CNTB stock price prediction 2025 2026 2027 2028 2029 2030
- CNTB fair value vs current price
- CNTB insider transactions and insider buying
- Is CNTB undervalued or overvalued?
- Connect Biopharma Holdings Ltd financial analysis — revenue, earnings, cash flow
- CNTB Piotroski F-Score and Altman Z-Score
- CNTB analyst price target and Smart Rating
Connect Biopharma Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Connect Biopharma Holdings Ltd (CNTB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Connect Biopharma Holdings Ltd (CNTB) Key Strengths (1)
51.38% held by institutions, strong professional interest
Supporting Valuation Data
Connect Biopharma Holdings Ltd (CNTB) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -98.70%, a shrinking business
Very expensive at 202.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Connect Biopharma Holdings Ltd (CNTB) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (202.49), Price/Book (2.83) suggest expensive pricing. Growth concerns include Revenue Growth at -98.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -66.80%, Operating Margin at -110481.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -66.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -98.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CNTB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CNTB's Price-to-Sales ratio of 202.49x trades 90% above its historical average of 106.44x (85th percentile), historically expensive. The current valuation is 1% below its historical high of 204.69x set in Mar 2026, and 5873% above its historical low of 3.39x in Sep 2025. Over the past 12 months, the PS ratio has expanded from ~3.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Connect Biopharma Holdings Ltd (CNTB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Connect Biopharma Holdings Ltd operates as a stable business with moderate growth and solid fundamentals. Revenue reached 762,000 with 99% decline year-over-year.
Key Findings
Spending 1458% of revenue (11M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 99% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -17M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Connect Biopharma Holdings Ltd.
Bottom Line
Connect Biopharma Holdings Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:06:42 AM
About Connect Biopharma Holdings Ltd(CNTB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe autoimmune diseases and inflammation. The company is headquartered in Taicang, China.